1. A beverage composition for promoting weight loss, comprising:
a stimulant agent;
a fat burning agent;
a carbohydrate blocking agent;
an anti-cholesterol agent;
an insulin sensitizing agent;
a sweetening agent;
an aromatic agent;
an antioxidant agent;
an anti-inflammatory agent;
a dietary fiber; and
a diuretic agent.
2. The beverage composition of claim 1, wherein the stimulant agent is Oolong tea.
3. The beverage composition of claim 2, wherein Oolong tea comprises a mixture of Taiwanese tea and Min Lan tea.
4. The beverage composition of claim 1, wherein the fat burning agent, the carbohydrate blocking agent, the anti-cholesterol agent, and the insulin sensitizing agent is Oolong tea.
5. The beverage composition of claim 1, wherein the sweetening agent is selected from the group consisting of stevia and inulin.
6. The beverage composition of claim 1, wherein the aromatic agent is selected from the group consisting of vanilla essential oil, and ocotea leaf.
7. The beverage composition of claim 1, wherein the antioxidant agent is cacao powder.
8. The beverage composition of claim 1, wherein the anti-inflammatory agent is selected from the group consisting of frankincense powder, vanilla essential oil, and ocotea leaf.
9. The beverage composition of claim 8, wherein the frankincense powder is derived from at least one of Boswellia sacra, Boswellia carterii, Boswellia thurifera, Boswellia frereana, and Boswelli bhaw-dajiana.
10. The beverage composition of claim 1, wherein the dietary fiber is selected from the group consisting of cacao powder and inulin.
11. The beverage composition of claim 1, wherein the diuretic agent is frankincense powder.
12. A method for promoting weight loss, the method comprising:
providing a beverage comprising:
a stimulant agent;
a fat burning agent;
a carbohydrate blocking agent;
an anti-cholesterol agent;
an insulin sensitizing agent;
a sweetening agent;
an aromatic agent;
an antioxidant agent;
an anti-inflammatory agent;
a dietary fiber; and
a diuretic agent; and
administering the beverage to a user before meals, with meals, before workouts, after workouts, or any combination thereof.
13. The method of claim 12, wherein the stimulant agent, the fat burning agent, the carbohydrate blocking agent, the anti-cholesterol agent, and the insulin sensitizing agent is Oolong tea.
14. The method of claim 13, wherein Oolong tea comprises a mixture of Taiwanese tea and Min Lan tea.
15. The method of claim 14, wherein the Oolong tea comprises approximately 46.31% of a serving of the beverage, by weight.
16. The method of claim 12, wherein the sweetening agent is inulin, and wherein inulin comprises approximately 27.33% of a serving of the beverage, by weight.
17. The method of claim 12, wherein the sweetening agent is stevia, and wherein stevia comprises approximately 0.21% of a serving of the beverage, by weight.
18. The method of claim 12, wherein the antioxidant agent is cacao powder, and wherein cacao powder comprises approximately 7.41% of a serving of the beverage, by weight.
19. The method of claim 12, wherein the anti-inflammatory agent is selected from the group consisting of frankincense powder, vanilla essential oil, and ocotea leaf.
20. A beverage composition for promoting weight loss, comprising:
Oolong tea from approximately 0.01 grams per serving to approximately 3.0 grams per serving;
stevia from approximately 0.0005 grams per serving to approximately 0.05 grams per serving;
inulin from approximately 0.05 grams per serving to approximately 1.5 grams per serving;
vanilla essential oil from approximately 0.005 grams per serving to approximately 0.5 grams per serving;
cacao powder from approximately 0.01 grams per serving to approximately 1.0 grams per serving;
frankincense powder from approximately 0.005 grams per serving to approximately 0.2 grams per serving; and
ocotea leaf from approximately 0.05 grams per serving to approximately 0.8 grams per serving.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound represented by the formula:
wherein:
Y is \u2014NH\u2014, \u2014O\u2014, \u2014S\u2014, or \u2014CH2\u2014;
R14 is a C1-C6 alkyl, amino-C1-C6 alkyl, hydroxy C1-C6 alkyl, C3-C10 cycloalkyl or methylureido group;
R15 and R17 are independently H, halo, or a C1-C6 alkyl group unsubstituted or substituted by one or more R5 groups;
R11 is H, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014C(O)NR12R13, \u2014C(O)(C6-C10 aryl), \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tNR12R13, \u2014SO2NR12R13 or \u2014CO2R12, wherein said C1-C6 alkyl, \u2014C(O)(C6-C10 aryl), \u2014(CH2)t(C6-C10 aryl), and \u2014(CH2)t(5 to 10 membered heterocyclic) moieties of the said R11 groups are unsubstituted or substituted by one or more groups;
each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, \u2014C(O)R8, \u2014C(O)OR8, \u2014OC(O)R8, \u2014OC(O)OR8, \u2014NR6C(O)R7, \u2014C(O)NR6R7, \u2014NR6R7, \u2014OR9, \u2014SO2NR6R7, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C6 alkylamino, \u2014(CH2)jO(CH2)qNR6R7, \u2014(CH2)tO(CH2)qOR9, \u2014(CH2)tOR9, \u2014S(O)j(C1-C6 alkyl), \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014C(O)(CH2)t(C6-C10 aryl), \u2014(CH2)tO(CH2)j(C6-C10 aryl), \u2014(CH2)tO(CH2)q(5 to 10 membered heterocyclic), \u2014C(O)(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)jNR7(CH2)qNR6R7, \u2014(CH2)jNR7CH2C(O)NR6R7, \u2014(CH2)jNR7(CH2)qNR9C(O)R8, (CH2)jNR7(CH2)tO(CH2)qOR9, \u2014(CH2)jNR7(CH2)qS(O)j(C1-C6 alkyl), \u2014(CH2)jNR7(CH2)tR6, \u2014SO2(CH2)t(C6-C10 aryl), and \u2014SO2(CH2)t(5 to 10 membered heterocyclic), the \u2014(CH2)q\u2014 and \u2014(CH2)t\u2014 moieties of the said R5 groups optionally include a carbon-carbon double or triple bond, and the alkyl, aryl and heterocyclic moieties of the said R5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, \u2014OH, \u2014C(O)R8, \u2014C(O)OR8, \u2014OC(O)R8, \u2014OC(O)OR8, \u2014NR6C(O)R7, \u2014C(O)NR6R7, \u2014(CH2)tNR6R7, C1-C6 alkyl, C3-C10 cydoalkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9;
each R6 and R7 is independently selected from H, OH, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, \u2014(CH2)tCN(CH2)tOR9, \u2014(CH2)tCN(CH2)tR9 and \u2014(CH2)tOR9, and the alkyl, aryl and heterocyclic moieties of the said R6 and R7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, \u2014C(O)R8, \u2014C(O)OR8, \u2014CO(O)R8, \u2014OC(O)OR8, \u2014NR9C(O)R10, \u2014C(O)NR9R10, \u2014NR9R10, C1-C6 alkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9, where when R6 and R7 are both attached to the same nitrogen, then R6 and R7 are not both bonded to the nitrogen directly through an oxygen;
each R8 is independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), and \u2014(CH2)t(5 to 10 membered heterocyclic);
t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;
each R9 and R10 is independently selected from H, \u2014OR6, C1-C6 alkyl, and C3-C10 cycloalkyl; and
each R12 and R13 is independently selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C3-C10 cycloalkyl), \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9, and the alkyl, aryl and heterocyclic moieties of the said R12 and R13 groups are unsubstituted or substituted with one or more substituents independently selected from R5, or R12 and R13 are taken together with the nitrogen to which they are attached to form a C5-C9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said C5-C9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl rings are unsubstituted or substituted with one or more R5 substituents, where R12 and R13 are not both bonded to the nitrogen directly through an oxygen;
or pharmaceutically acceptable salts or solvates thereof.
2. A compound, salt, or solvate according to claim 1, wherein R11 is \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014C(O)NR12R13, \u2014(CH2)tNR12R13, \u2014SO2NR12R13 or \u2014CO2R12.
3. A compound of claim 2, wherein R11 is \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014C(O)NR12R13, \u2014SO2NR12R13 or \u2014CO2R12.
4. A compound of claim 3, wherein R11 is \u2014(CH2)t(5 to 10 membered heterocyclic) or \u2014C(O)NR12R13.
5. A compound of claim 4, wherein R11 is \u2014C(O)NR12R13, wherein R12 and R13 are independently selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C3-C10 cycloalkyl), \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9.
6. A compound of claim 5, wherein R11 is \u2014C(O)NR12R13, and wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a C5-C9 azabicyclic, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said C5-C9 azabicyclic, azindinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring is unsubstituted or substituted by 1 to 5 R5 substituents.
7. A compound of claim 6, wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring, wherein said pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl ring is unsubstituted or substituted with 1 to 5 R5 substituents.
8. A compound of claim 7, wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, pipendinyl, piperazinyl, morpholinyl, or thiomorpholinyl ring, wherein said pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl ring is unsubstituted or substituted with 1 to 5 R5 substituents.
9. A compound of claim 8, wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl or piperidinyl ring, wherein said pyrrolidinyl or piperidinyl ring is unsubstituted or substituted with 1 to 5 R5 substituents.
10. A compound of claim 9, wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl ring, wherein said pyrrolidinyl is unsubstituted or substituted with 1 to 5 R5 substituents.
11. A compound of claim 10, wherein R12 and R13 are taken together with the nitrogen to which they are attached to form a pyrrolidin-1-yl ring, wherein said pyrrolidin-1-yl ring is unsubstituted or substituted with 1 to 5 R5 substituents.
12. A compound of claim 4, wherein R11 is a \u2014(CH2)t(5 to 10 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R5 groups.
13. A compound of claim 12, wherein R11 is a \u2014(CH2)t(5-8 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R5 groups.
14. A compound of claim 13, wherein R11 is a \u2014(CH2)t(5 or 6 membered heterocyclic) group is unsubstituted or substituted with 1 to 5 R5 groups.
15. A compound of claim 14, wherein R11 is a \u2014(CH2)t(5 membered heterocyclic) group unsubstituted or substituted with 1 to 5 R5 groups.
16. A compound of claim 15, wherein R11 is a thiazolyl, unsubstituted or substituted by 1 to 5 R5 groups.
17. A compound of claim 15, wherein R11 is an imidazolyl, unsubstituted or substituted by 1 to 5 R5 groups.
18. A compound of claim 1, wherein R14 is methyl.
19. A compound represented by the formula:
wherein:
R14 is a C1-C6 alkyl, amino-C1-C6 alkyl, hydroxy C1-C6 alkyl, C3-C10 cycloalkyl or methylureido group;
R15 and R17 are independently H, halo, or a C1-C6 alkyl group;
R11 is a heteroaryl group unsubstituted or substituted by one or more halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, \u2014C(O)R8, \u2014C(O)OR8, \u2014OC(O)R8, \u2014OC(O)OR8, \u2014NR6C(O)R7, \u2014C(O)NR6R7, \u2014NR6R7, \u2014OR9, \u2014SO2NR6R7, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)jO(CH2)qNR6R7, \u2014(CH2)tO(CH2)qOR9, \u2014(CH2)tOR9, \u2014S(O)j(C1-C6 alkyl), \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014C(O)(CH2)t(C6-C10 aryl), \u2014(CH2)tO(CH2)j(C6-C10 aryl), \u2014(CH2)tO(CH2)q(5 to 10 membered heterocyclic), \u2014C(O)(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)jNR7(CH2)qNR6R7, \u2014(CH2)jNR7CH2C(O)NR6R7, \u2014(CH2)jNR7(CH2)qNR9C(O)R8, \u2014(CH2)jNR7(CH2)tO(CH2)qOR9, \u2014(CH2)jNR7(CH2)qS(O)j(C1-C6 alkyl), \u2014(CH2)jNR7\u2014(CH2)tR6, \u2014SO2(CH2)t(C6-C10 aryl), and \u2014SO2(CH2)t(5 to 10 membered heterocyclic), the \u2014(CH2)q\u2014 and \u2014(CH2)t\u2014 moieties of the said R5 groups optionally include a carbon-carbon double or triple bond, and the alkyl, aryl and heterocyclic moieties of the said R5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, \u2014OH, \u2014C(O)R8, \u2014C(O)OR8, \u2014OC(O)R8, \u2014OC(O)OR8, \u2014NR6C(O)R7, \u2014C(O)NR6R7, \u2014(CH2)tNR6R7, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9;
each R6 and R7 is independently selected from H, OH, C1-C6 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, \u2014(CH2)tCN(CH2)tOR9, \u2014(CH2)tCN(CH2)tR9 and \u2014(CH2)tOR9, and the alkyl, aryl and heterocyclic moieties of the said R6 and R7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, \u2014C(O)R8, \u2014C(O)OR8, \u2014CO(O)R8, \u2014OC(O)OR8, \u2014NR9C(O)R10, \u2014C(O)NR9R10, \u2014NR9R10, C1-C6 alkyl, \u2014(CH2)t(C6-C10 aryl), \u2014(CH2)t(5 to 10 membered heterocyclic), \u2014(CH2)tO(CH2)qOR9, and \u2014(CH2)tOR9, where when R6 and R7 are both attached to the same nitrogen, then R6 and R7 are not both bonded to the nitrogen directly through an oxygen;
each R8 is independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), and \u2014(CH2)t(5 to 10 membered heterocyclic);
each R9 and R10 is independently selected from H, C1-C6 alkyl, and C3-C10 cycloalkyl;
t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;
or pharmaceutically acceptable salts or solvates of said compounds.
20. A compound of claim 19, wherein R14 is methyl.
21. A compound represented by the formula III:
wherein:
R14 is a C1-C6 alkyl, amino-C1-C6 alkyl, hydroxy C1-C6 alkyl, C3-C10 cycloalkyl or methylureido group;
R15 and R17 are independently H, halo, or a C1-C6 alkyl group; and
R11 is a heterocyclic or a heteroaryl group unsubstituted or substituted by one or more groups selected from \u2014C(O)OR8, C1-C6 alkyl, and \u2014(CH2)tOR9;
each R8 is independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, \u2014(CH2)t(C6-C10 aryl), and \u2014(CH2)t(5 to 10 membered heterocyclic);
each R9 is independently selected from H, C1-C6 alkyl, and C3-C10 cycloalkyl; and
t is an integer from 0 to 6; j is an integer from 0 to 2; q is an integer from 2 to 6;
or pharmaceutically acceptable salts or solvates of said compounds.
22. A compound of claim 21, wherein R14 is methyl.
23. A compound of claim 1, wherein R14 is cyclopropyl.
24. A compound of claim 19, wherein R14 is cyclopropyl.
25. A compound of claim 21, wherein R14 is cyclopropyl.
26. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.